<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="1454">
  <stage>Registered</stage>
  <submitdate>28/07/2004</submitdate>
  <approvaldate>28/07/2004</approvaldate>
  <actrnumber>ACTRN12606000301561</actrnumber>
  <trial_identification>
    <studytitle>TOAD - Timing of androgen deprivation intervention in prostate cancer patients with a rising PSA</studytitle>
    <scientifictitle>A collaborative randomised phase III trial: The timing Of intervention with Androgen Deprivation in prostate cancer patients with a rising Prostate Specific Antigen (PSA)</scientifictitle>
    <utrn />
    <trialacronym>TOAD</trialacronym>
    <secondaryid>VCOG PR 1-03</secondaryid>
    <secondaryid>TROG 03.06</secondaryid>
    <secondaryid>National Clinical Trials Registry: NCTR580</secondaryid>
    <secondaryid>Trans-Tasman Radiation Oncology Group Inc (TROG): TROG 03.06</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Prostate cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Prostate</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Patients will be randomised to receive androgen deprivation therapy either immediately (experimental arm)</interventions>
    <comparator>Patients will be randomised to receive androgen deprivation therapy delayed for at least 2 years  or until evidence of significant disease progression (control arm).</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The primary endpoint of the trial is death from any cause</outcome>
      <timepoint>Measured at 6 monthly assessments</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Cancer specific survival</outcome>
      <timepoint>6 monthly for 5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Clinical progression</outcome>
      <timepoint>6 monthly for 5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to first androgen independence</outcome>
      <timepoint>6 monthly for 5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Complication rate incidence and timing (eg cord compression, pathological fracture)</outcome>
      <timepoint>6 monthly for 5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Treatment related morbidity (including cognitive, osteoporosis)</outcome>
      <timepoint>6 monthly for 5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Quality of life</outcome>
      <timepoint>6 monthly for 5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Prognostic factors for progression (delayed group)</outcome>
      <timepoint>6 monthly for 5 years</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>STUDIES 1 AND 2- Histologically confirmed adenocarcinoma of the prostate- Accessible for follow-up- Informed consent to be randomised to immediate or delayed androgen deprivation- Males aged 18 years and overINCLUSION CRITERIA STUDY 1 PSA relapse after definitive radical treatment- No evidence of metastatic disease on staging investigations (bone scan, abdomino-pelvic CT scan)- Prior androgen deprivation limited to a maximum of seven months neo-adjuvant/concurrent treatment, completed at least 12 months prior to study entryINCLUSION CRITERIA STUDY 2- Not suitable for radical treatment at primary diagnosis.- Decision not to treat curatively- No symptoms due to local or metastatic disease requiring radiation or immediate hormone therapy- No prior androgen deprivation therapy</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Males</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Significant co-morbidity limiting life expectancy to less than 5 years- Patients with symptomatic disease requiring therapy- Previous androgen deprivation for longer than 7 months (Study 1)- Diagnosis of PSA relapse or incurable disease more than six months prior to randomisation- Patients entered into TROG studies 96.01 or RADAR- Patients with a PSA doubling time of less than 3 months (Study 1)</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Randomisation is performed centrally using computer software.</concealment>
    <sequence>Treatment is allocated using a database embedded dynamically balanced randomisation method.</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>1/08/2004</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>750</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Charities/Societies/Foundations</primarysponsortype>
    <primarysponsorname>The Cancer Council Victoria</primarysponsorname>
    <primarysponsoraddress>1 Rathdowne St, Carlton South, 3053, VIC</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>National Health &amp; Medical Research Council</fundingname>
      <fundingaddress>National Health and Medical Research Council
GPO Box 1421
Canberra ACT 2601</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>untied pharmaceutical company grants</fundingname>
      <fundingaddress>Hospira
Level 6, 390 St Kilda Road
Melbourne, VIC, 3004</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Other Collaborative groups</sponsortype>
      <sponsorname>Trans Tasman Radiation Oncology Group (TROG)</sponsorname>
      <sponsoraddress>Dept of Radiation Oncology
Newcastle Mater Misericordiae Hospital
Locked Bag7, NHMRC NSW 2310</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a clinical trial for patients with prostate cancer. The aim of the project is to provide information about the best timing to start treatment in men who have a rising PSA (prostate specific antigen) blood test, after having had treatment with the aim of curing their prostate cancer.  In some men, the surgery or radiotherapy given initially in the attempt to cure the cancer is not successful.  One of the earliest ways of detecting recurrence of the cancer in these men is with the PSA blood test, which can detect activity of the cancer months or years before other tests, and usually long before any symptoms appear.  
We know that treatment with hormone therapy  removing the male hormone testosterone  is helpful in controlling advanced disease causing symptoms, although it is not a cure.  This is called androgen deprivation, testosterone being an androgen hormone. The cancer cells are deprived of a source of energy, keeping them under control for a while, but eventually they tend to start growing again in spite of the treatment.  We know that using androgen deprivation usually causes the PSA level in men to fall, including men in your situation who have no other signs of active cancer.  What we do not know is whether using androgen deprivation immediately the PSA starts to rise will prolong life more than waiting to start treatment until there are other signs that the disease is progressing.
It would be simple to start everyone on treatment with androgen deprivation if there were no side effects with the treatment. However, there are a number of side effects that may interfere with day-to-day living. These include (but are not limited to): hot flushes, tiredness, anaemia, and loss of muscle mass and bone density. There may be weight gain, and nipple tenderness or swelling. Some men notice changes in mental function, or shortness of breath. Most also find that sex drive and erectile function, if normal before starting treatment, cease.  Quality of life may be affected. If androgen deprivation therapy is ceased, some of the side effects (such as loss of sex drive, loss of muscle bulk or bone mineral density) may be halted or reversed. Generally the standard approach would be to delay introducing treatment until the disease progresses.
So the purpose of the study is to see whether immediate treatment is better or worse than delayed treatment in terms of prolonging lifespan, balanced against the effects on the quality of life.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Alfred Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>25/10/2004</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Campbelltown Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>6/12/2005</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Cham, Mr Chee Wee</ethicname>
      <ethicaddress />
      <ethicapprovaldate>19/08/2005</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Christchurch Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>19/04/2005</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname />
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Concord Repatriation Hosp</ethicname>
      <ethicaddress />
      <ethicapprovaldate>5/10/2004</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Dunedin Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>24/06/2005</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>East Coast Cancer Centre</ethicname>
      <ethicaddress />
      <ethicapprovaldate>30/11/2004</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Geelong Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>4/11/2004</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname />
      <ethicaddress />
      <ethicapprovaldate>28/04/2006</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Liverpool Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>6/11/2004</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Mander, Mr Julian</ethicname>
      <ethicaddress />
      <ethicapprovaldate>19/05/2006</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Mater QRI</ethicname>
      <ethicaddress />
      <ethicapprovaldate>9/09/2004</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Monash Medical Centre</ethicname>
      <ethicaddress />
      <ethicapprovaldate>19/04/2006</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Nepean Cancer Care Centre</ethicname>
      <ethicaddress />
      <ethicapprovaldate>29/03/2005</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Newcastle Mater</ethicname>
      <ethicaddress />
      <ethicapprovaldate>18/03/2005</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Peter MacCallum Cancer Centre</ethicname>
      <ethicaddress />
      <ethicapprovaldate>24/08/2004</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Princess Alexandra Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>30/08/2004</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname />
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Repatriation General Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>4/08/2004</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Brisbane Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>3/08/2004</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Prince Alfred</ethicname>
      <ethicaddress />
      <ethicapprovaldate>23/08/2004</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Sinclair, Mr Graham</ethicname>
      <ethicaddress />
      <ethicapprovaldate>28/06/2005</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Sir Charles Gairdner Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>19/12/2005</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Syme, Mr Rodney</ethicname>
      <ethicaddress />
      <ethicapprovaldate>1/03/2005</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>St George Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>16/03/2005</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Vivian, Mr Justin</ethicname>
      <ethicaddress />
      <ethicapprovaldate>19/05/2006</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Waikato Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>23/11/2004</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Wellington Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname />
      <ethicaddress />
      <ethicapprovaldate>6/08/2004</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Westmead Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>26/10/2004</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Auckland City Hospital</ethicname>
      <ethicaddress>Waikato DHB, Regional Cancer Centre, Private Bag, 3200 Hamilton, NZ</ethicaddress>
      <ethicapprovaldate>26/10/2006</ethicapprovaldate>
      <hrec>WAI/04/07/058</hrec>
      <ethicsubmitdate>26/10/2006</ethicsubmitdate>
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal North Shore Hospital</ethicname>
      <ethicaddress>Research Office, Level 4, Vindin House, RNSH, Pacific Hwy, St Leonards, NSW 2065</ethicaddress>
      <ethicapprovaldate>16/09/2006</ethicapprovaldate>
      <hrec>0608-144M</hrec>
      <ethicsubmitdate>16/09/2006</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Dr Henry Woo</ethicname>
      <ethicaddress>New South Wales Cancer Council</ethicaddress>
      <ethicapprovaldate>10/01/2005</ethicapprovaldate>
      <hrec>123</hrec>
      <ethicsubmitdate>10/01/2005</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Illawarra Cancer Care Centre</ethicname>
      <ethicaddress>SE Sydney and Illawarra Area Health Service Health and Medical HREC</ethicaddress>
      <ethicapprovaldate>14/05/2008</ethicapprovaldate>
      <hrec>CT08/001</hrec>
      <ethicsubmitdate>14/05/2008</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Prof Gillian Duchesne</name>
      <address>Director  Radiation Oncology
Peter MacCallum Cancer Centre
Locked Bag 1
A'Beckett Street
Melbourne  Victoria 8001</address>
      <phone>+61(0)3 9656 1004</phone>
      <fax>+61(0)3 9656 1424</fax>
      <email>Gillian.Duchesne@petermac.org</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Deborah Howell</name>
      <address>The Cancer Council Victoria
1 Rathdowne Street
Carlton VIC 3053</address>
      <phone>+61(0)3 9635 5179</phone>
      <fax>+61(0)3 9635 5410</fax>
      <email>Deborah.Howell@cancervic.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>